4th ACTC | Advances in Circulating Tumor Cells | Liquid Biopsy: Latest Advances and Future Challenges

Tentative Program

ACTC2019 PRELIMINARY PROGRAM

Day 1: Wednesday, October 2nd

07:30 – 08:30 Registration
08:30 – 09:00 Welcome Address
Chairperson’s Opening Remarks
07:30 – 08:30 Registration
Plenary Lecture Session 1:
Recent Advances in the biology of metastasis
9:00 – 9:30
PL1-1
“Liquid Biopsy: Current clinical application and challenges”
Klaus Pantel, University Medical Centre Hamburg Eppendorf,
Hamburg, Germany
9:30 – 10:00
PL1-2
“Epithelial mesenchymal transition in carcinoma; therapeutic
intervention”
Jean Paul Thiery, University Paris Denis Diderot, Paris, France
10:00 – 10:30
PL1-3
“E-selectin dependent vascular niche for bone metastasis”
Yibin Kang, Princeton University, Princeton, New Jersey, USA
10:30 – 11:00
Poster viewing and networking coffee break in the exhibition hall
11:00 – 11:30
PL1-4
“Talk title to be announced”
George Calin, University of Texas MD Anderson Cancer Center,
Houston, USA
11:30 – 12:00
PL1-5
“Strategies to Exploit the Biology of Exosomes for Diagnosis
and Treatment of Cancer”
Raghu Kalluri, University of Texas MD Anderson Cancer Center,
Houston, TX, USA
12:00 – 12:30
PL1-6
“Tumor-educated platelets for the detection of cancer”
Thomas Wurdinger, VU University Medical Center, Netherlands
12:30 – 13:30
Lunch break
13:30 – 15:30 ORAL PRESENTATIONS, Session 1
15:30 – 16:30
Poster session 1 and networking coffee break in the exhibition hall
Plenary lecture session 2:
New insights on the potential of liquid biopsy
16:30 – 17:00
PL2-1
“Organs-on-a-chip technology and single cell drug testing”
Stefanie S. Jeffrey, Stanford University, School of Medicine,
Stanford, USA
17:00 – 17:30
PL2-2
“Circulating tumor DNA (ctDNA) and miRNA: Clinical utility in
assessing cancer progression”
Dave Hoon, John Wayne Cancer Institute, Santa Monica, USA
17:30 – 18:00
PL2-3
“Genotyping colorectal cancers in the blood”
Alberto Bartelli, Univ of Torino- Candiolo Cancer Institute, Torino,
Italy
18:00 – 21:00
Welcome reception

Day 2: Thursday, October 3rd

Plenary lecture session 3:
Liquid biopsy in breast cancer
8:30 – 9:00
PL3-1
“Liquid biopsies as a potential therapeutic tool in head and
neck cancer”
Amanda Psyrri, University of Athens Medical School, Athens,
Greece
9.00 – 9.30
PL3-2
“PMN-MDSCs Enhance CTC Metastatic Properties through
Reciprocal Interactions via Nodal/Notch/Nodal Signalling”
Dario Marchetti, Baylor College of Medicine, USA
9:30 – 10:00
PL3-3
“Liquid Biopsy in early breast cancer – is there any clinical
utility?”
Wolfgang Janni, University of Ulm, Germany
10:00 – 10:30
PL3-4
“Liquid biopsy for precision medicine in breast cancer:
challenges and opportunities”
Michail Ignatiadis, Jules Bordet Institute Brussels, Belgium.
10:30 – 11:00
Poster viewing and networking coffee break in the exhibition hall
11:00 – 11:30
PL3-5
Title to be announced
Carlos Caldas, MD, PhD, University of Cambridge, Cambridge,
UK
11:30 – 12:00
PL3-6
“Liquid Biopsy in MBC: Recognizing The Bad, The Good and
the Ugly”
Massimo Cristofanilli, Robert H Lurie Comprehensive Cancer
Center Feinberg School of Medicine, Chicago, USA
12:00 – 12:30
PL3-7
Title to be announced
Jean-Yves Pierga, Institute Curie and University Paris Descartes,
Paris, France
12:30 – 13:30
Lunch break
13:30 – 14:30 ORAL PRESENTATIONS, Session 2
14:30 – 15:30
Industry sponsored oral presentations
14:30 – 15:00
Angle, Gold Sponsor: Title to be announced
15:00 – 15:10
ALS: Title to be announced
15:10 – 15:20
RareCyte: Title to be announced
15:20 – 15:30
Gilupi: Title to be announced
15:30 – 16:30
Poster session 2 and networking coffee break in the exhibition hall
16:30 – 17:00  Travel Award Oral Presentations
Plenary lecture session 4:
Liquid biopsy: recent progress in lung cancer
17:00 – 17:30
PL4-1
Title to be announced
Caroline Dive, University of Manchester, UK
17:30 – 18:00
PL4-2
“Tumor Heterogeneity Inferred from Single CTC Sequencing
and CTC-derived explants (CDX)”
Francoise Farace, Gustave Roussy, Villejuif, France
Free evening – faculty dinner

Day 3: Friday, October 4th

Plenary lecture session 5:
Recent advances on the isolation, enumeration and molecular
characterization of CTCs
8:30 – 9:00
PL5-1
 “No Cell Left Behind: tracing molecular evolution”
Peter Kuhn, The Bridge@USC, Los Angeles, CA, USA
9.00 – 9.30
PL5-2
 Title to be announced
Richard J. Cote, Washinghton University in St Louis, St Louis
9:30 – 10:00
PL5-3
Title to be announced
Leon Terstappen, University of Twente, the Netherlands
10:00 – 10:30
PL5-4
“Development and clinical evaluation of multiplex molecular
assays for CTC molecular characterization”
Evi Lianidou, University of Athens, Athens, Greece
10:30 – 11:00
Poster viewing and networking coffee break in the exhibition hall
11:00 – 11:30
PL5-5
“Circulating Tumor Cells: Finding Rare Events for A Huge
Knowledge of Cancer Dissemination”
Catherine Alix-Panabieres, CHRU Montpellier, France
11:30 – 12:00
PL5-6
“Genomics of individual circulating tumor cells as biomarker
for early drug development”
Nikolas Stoecklein, Heinrich Heine University, Dusseldorf,
Germany
12:00 – 12:30
PL5-7
“Molecular characterization of single circulating tumor cells
in breast and ovarian cancer”
Sabine Kasimir-Bauer, University Hospital of Essen, Essen,
Germany
12:30 – 13:30
Lunch break
13:30 – 14:30 ORAL PRESENTATIONS, Session 3
14:30 – 15:30
Industry sponsored oral presentations
14:30 – 15:00
 Menarini Silicon Biosystems, Platinum Sponsor: Title to be announced
15:00 – 15:30
Agena, Gold Sponsor: Title to be announced
15:30 – 16:30
Poster session 3 and networking coffee break in the exhibition hall
Plenary lecture session 6:
Liquid biopsies: recent advances on prostate cancer
16:30 – 17:00
PL6-1
“Dissecting the molecular profiles of circulating tumour cells
in xenograft models of prostate cancers”
Rik Thomson, Queensland University of Technology, Brisbane,
Australia
17:00 – 17:30
PL6-2
“Using liquid biopsy as a treatment-selection tool in advancedprostate cancer”
Emmanuel Antonarakis, Johns Hopkins Sidney Kimmel
Comprehensive Cancer Center Baltimore, Maryland, USA
17:30 – 18:00
PL6-3
Title to be announced
Howard Scher, Memorial Sloan Kettering Cancer Research, New
York, USA
20.00 – ??? GALA DINNER PARTY

Day 4: Saturday, October 5th

Plenary lecture session 7:
Circulating tumor DNA technologies and applications in clinical practice
8:30 – 9:00
PL7-1
“Novel digital PCR and mutation enrichment technologies for
the analysis of clinically relevant DNA alterations in
circulating-DNA”
Mike Makrigiorgos, Dana-Farber Cancer Institute and Harvard
Medical School, Boston, USA
9.00 – 9.30
PL7-2
Title to be announced
Michael Neumaier, University of Heidelberg, Mannheim, Germany
9:30 – 10:00
PL7-3
“Epigenetic signatures in cell-free DNA”
Michael Speicher, Medical University of Graz, Austria,
10:00 – 10:30
PL7-4
 Applications of liquid biopsies in the early detection of
cancer.
Nicholas Papadopoulos, Sidney Kimmel Comprehensive Cancer
Center, Johns Hopkins University School of Medicine, Baltimore,
USA
10:30 – 11:00
Poster viewing and networking coffee break in the exhibition hall
Plenary lecture session 8:
Future challenges in liquid biopsies
11:00 – 11:30
PL8-1
“IMI’s CANCER-ID: Standardizing Liquid Biopsy for clinical
use – Lessons learned from an international Public-Private
Partnership”
Thomas Schlange, PhD, Senior Biomarker Scientist, Global
Biomarker Research, Bayer Pharma, Germany
11:30 – 12:00
PL8-2
 “Regulatory Considerations for Utilizing Liquid Biopsies in
Drug and Diagnostics Development”
Garry Kelloff, M.D., Special Advisor, CIP, DCTD, National Cancer
Institute, NIH, USA
12:00 – 13:00
Panel Discussion: Liquid Biopsy: Future directions
13:00 – 13:30
Travel awards – best poster awards
Closing remarks
Evi Lianidou and Klaus Pantel
14.00 – 20.00
Corfu town sightseeing (optional)

4th ACTC | Advances in Circulating Tumor Cells | Liquid Biopsy: Latest Advances and Future Challenges